CART cells for advanced stomach and pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to target a protein (Claudin18.2) found on some stomach and pancreatic cancer cells. The goal is to see if these specially designed cells can shrink tumors and slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have advanced stomach or pancreatic cancer that has continued to grow despite previous treatments.
- Your tumor tests positive for a protein called Claudin18.2 (a special marker).
- You have at least one tumor that can be measured on scans.
- You are generally in good health (able to care for yourself, with adequate organ function).
- You do not have brain metastases, major bleeding risks, or uncontrolled infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.
This trial tests a new type of cell therapy (CAR-T) that targets two proteins, CLDN18.2 and PD-L1, found on some cancer cells. It is for people with advanced solid tumors like stomach, esophageal, or pancreatic cancer that have stopped responding to standard treatments.
This trial tests a special type of immune therapy called CAR-T, which uses your own blood cells to attack cancer cells that have a specific marker, Claudin 18.2. It may be an option for people with advanced solid tumors (especially pancreatic cancer) that have not responded to other treatments.
This trial tests a new type of cell therapy (CAR-T) that targets two markers on pancreatic cancer cells. It's for people with advanced pancreatic cancer who have already tried standard chemotherapy.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests a new type of cell therapy (CAR-T) that targets a protein called Claudin18.2 found on some stomach, esophagus, and gastroesophageal junction cancers. The goal is to see if this treatment can shrink tumors or stop them from growing when other treatments have stopped working.
Hear when a new Advanced Gastric and Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.